Ogasawara, T.; Hashimoto, K.; Shindo, T.; Kobayashi, K.; Tanaka, T.; Fukuta, F.; Kobayashi, G.; Kato, R.; Miyamoto, S.; Kunishima, Y.;
et al. Optimal Timing of Treatment Initiation in Non-Metastatic Castration-Resistant Prostate Cancer Based on PSA Level and Doubling Time for Prognostic Benefit. Cancers 2025, 17, 3641.
https://doi.org/10.3390/cancers17223641
AMA Style
Ogasawara T, Hashimoto K, Shindo T, Kobayashi K, Tanaka T, Fukuta F, Kobayashi G, Kato R, Miyamoto S, Kunishima Y,
et al. Optimal Timing of Treatment Initiation in Non-Metastatic Castration-Resistant Prostate Cancer Based on PSA Level and Doubling Time for Prognostic Benefit. Cancers. 2025; 17(22):3641.
https://doi.org/10.3390/cancers17223641
Chicago/Turabian Style
Ogasawara, Takuto, Kohei Hashimoto, Tetsuya Shindo, Ko Kobayashi, Toshiaki Tanaka, Fumimasa Fukuta, Genki Kobayashi, Ryuichi Kato, Shintaro Miyamoto, Yasuharu Kunishima,
and et al. 2025. "Optimal Timing of Treatment Initiation in Non-Metastatic Castration-Resistant Prostate Cancer Based on PSA Level and Doubling Time for Prognostic Benefit" Cancers 17, no. 22: 3641.
https://doi.org/10.3390/cancers17223641
APA Style
Ogasawara, T., Hashimoto, K., Shindo, T., Kobayashi, K., Tanaka, T., Fukuta, F., Kobayashi, G., Kato, R., Miyamoto, S., Kunishima, Y., & Masumori, N.
(2025). Optimal Timing of Treatment Initiation in Non-Metastatic Castration-Resistant Prostate Cancer Based on PSA Level and Doubling Time for Prognostic Benefit. Cancers, 17(22), 3641.
https://doi.org/10.3390/cancers17223641
